Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen reports positive phase III data for Edurant

Janssen reports positive phase III data for Edurant

21st July 2011

Janssen has published positive phase III clinical trial data for Edurant, its treatment for adult HIV patients.

The drug has been studied in comparison to efavirenz in a pair of trials, Echo and Thrive, which evaluated efficacy, safety and virology profile over a period of 96 weeks.

Pooled data from both studies showed that Edurant was able to meet its primary goal of non-inferiority in terms of effectiveness in lowering viral load, with results after 96 weeks consistent with primary analysis conducted after 46 weeks.

Dr Calvin Cohen, lead clinical investigator of the Edurant phase III trials, said: "Edurant remains an important new option for treatment-naive patients and their physicians."

The treatment has been ratified in the US since May 2011, with the European Medicines Agency having also received an application for approval.

Earlier this week, Janssen announced the sale of its Ortho Dermatologics division to Valeant Pharmaceuticals, a deal which is expected to close before the end of the year.ADNFCR-8000103-ID-800628890-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.